Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Argentina Market

Release time:Oct 30, 2023

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that it has established a licensing and commercialization agreement with Ultra Pharma S.A.(“UPL”), for its product Adalimumab Biosimilar. Under the agreement, UPL is responsible for the local filling finish, registration and commercialization in Argentina.

Mr. Huiguo Hu, the Board member and Senior Vice President of Mabwell, said: “We are pleased to build the strategic collaboration with UPL for Argentine market, work together to local filling finish and commercialize adalimumab biosimilar in Argentina. Argentina is the third biggest pharmaceutical market in LATAM. Argentina is the first major Latin American country to join the Belt and Road Initiative in February 2022. We trust that it will further improve the accessibility of adalimumab to local patients in Argentina.” 


About UPL

UPL is a 100% Argentine pharmaceutical company, which was founded in 2000. UPL has 2 manufacturing units, different pharmaceutical products in 6 therapeutic areas, which is a leading pharmaceutical company in oncology and hematology market in Argentina. UPL is an important and active participant in the bidding of the national government, as well as the provincial governments of Argentina. Except for Argentina, UPL builds several subsidiaries in Colombia, Ecuador, Peru and other countries to have the deep marketing promotion and sales in the countries.